News Room

19

Jul 22

Agilent’s Certified Pre-Owned Instruments Program Receives Environmental Award

Agilent’s Certified Pre-Owned Instruments Program Receives Environmental Award Agilent Technologies Inc. (NYSE: A) today announced the company’s Certified Pre-Owned Instruments...
Read More

5

Apr 22

Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Esophageal Squamous Cell Carcinoma

Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Esophageal Squamous Cell Carcinoma Agilent Technologies Inc....
Read More

5

Apr 22

Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Muscle-Invasive Urothelial Carcinoma (MIUC)

Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Muscle-Invasive Urothelial Carcinoma (MIUC) Agilent Technologies Inc....
Read More

7

Jan 22

The Innovators 2021

The Innovators 2021     R-TRACKER: A TRUE MILESTONE IN SPECIMEN TRACEABILITY Traceability is of paramount importance for patient safety...
Read More

2

Nov 21

Agilent Names John Palma to Lead Global Medical Affairs Organization

Agilent Names John Palma to Lead Global Medical Affairs Organization Agilent Technologies, Inc. (NYSE: A) today announced that John Palma...
Read More

21

Oct 21

Agilent PD-L1 IHC 28-8 pharmDx Receives CE-IVD Mark as a Companion Diagnostic Test in Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Agilent PD-L1 IHC 28-8 pharmDx Receives CE-IVD Mark as a Companion Diagnostic Test in Advanced or Metastatic Gastric, Gastroesophageal Junction,...
Read More

13

Oct 21

Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer

Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer Agilent Technologies Inc. (NYSE:...
Read More

29

Sep 21

GE Healthcare Debuts MyoSPECT, A Next-Generation Nuclear Medicine Cardiology System That Gets to the Heart of Challenging Cardiovascular Cases

GE Healthcare Debuts MyoSPECT, A Next-Generation Nuclear Medicine Cardiology System That Gets to the Heart of Challenging Cardiovascular Cases GE...
Read More

17

Sep 21

Start of the Magnetic Resonance Outcome (MRO) study to evaluate the ClearCoast™ MRI system

Start of the Magnetic Resonance Outcome (MRO) study to evaluate the ClearCoast™ MRI system The ClearCoast™ MRI system makes it...
Read More

17

Sep 21

New name: ClearSight™ has become ClearCoast™

New name: ClearSight™ has become ClearCoast™ ClearCut Medical Ltd. has changed the name of its diffusion-weighted MRI technology for intraoperative...
Read More
1 2 3 6